MX1 encodes myxovirus resistance protein A (MxA), an interferon-induced dynamin-like GTPase that functions as a critical antiviral restriction factor against multiple RNA viruses 1. MX1 inhibits influenza A virus (IAV) replication through multiple mechanisms: it blocks endocytic trafficking of incoming viral particles, decreases nucleoprotein synthesis, and orchestrates cytoplasmic sequestration of newly synthesized viral ribonucleoproteins (vRNPs) through dynein-dependent retrograde transport to the microtubule organizing center 2. The protein also restricts other viruses including H5N1 and H7N9 avian influenza strains 31. Clinically, MX1 variants have significant disease relevance. Rare heterozygous MX1 mutations are strongly associated with susceptibility to zoonotic avian influenza H7N9 infection in humans; most variants lose antiviral activity and exert dominant-negative effects on wild-type MxA function 1. Blood MX1 expression serves as a superior biomarker for early viral infection detection, correlating with rapid interferon-stimulated gene induction across cell types and preceding PCR detection of replicative infection 4. Additionally, MX1 expression in monocytes (MX1+ monocytes) emerges as a critical mediator of immunomodulation in therapeutic contexts 5. These findings establish MX1 as a key host defense determinant controlling zoonotic and seasonal influenza infections.